Related Experiment Video
Updated: Apr 28, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Stroke in atrial fibrillation patients already on oral anticoagulant: What more can be done?]
Emmanuel Touzé1, Doina Ciocanu1
1Université Caen Basse Normandie, CHU Côte-de-Nacre, service de neurologie et unité neurovasculaire, 14000 Caen, France.
Insights
Despite oral anticoagulants, 1-3% of atrial fibrillation patients experience ischemic stroke annually. Management strategies exist but lack specific study evaluation for these challenging cases.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Context:
- Atrial fibrillation (AF) patients on oral anticoagulants (OACs) still face ischemic stroke risks.
- Annual incidence of ischemic stroke in OAC-treated AF patients is 1-3%.
- Potential causes include OAC efficacy fluctuations, non-cardioembolic stroke, or inadequate anticoagulation.
Purpose:
- To review therapeutic options for ischemic stroke in AF patients despite OAC therapy.
- To highlight the lack of specific clinical evaluations for these management strategies.
Summary:
- Ischemic strokes in OAC-treated AF patients can stem from various mechanisms.
- Current therapeutic approaches include enhanced patient education, switching anticoagulants, adding aspirin, or percutaneous left-appendage closure.
- These interventions require further rigorous study to establish optimal use.
Impact:
- Informs clinical decision-making for managing complex stroke cases in AF.
- Identifies critical gaps in evidence for stroke prevention strategies in atrial fibrillation.
- Guides future research priorities for improving anticoagulation efficacy and stroke risk reduction.
Abstract:
Oral anticoagulants dramatically reduce the risk of embolic stroke in patients with atrial fibrillation (AF). However, each year, 1 to 3 % of patients will present an ischemic stroke despite being on oral anticoagulant. These events can result from efficacy fluctuations, non-cardioembolic stroke, or insufficient efficacy despite appropriate anticoagulation. There are several therapeutic options depending on presumed mechanism of ischemic stroke. However, none of these options has been specifically evaluated in appropriate studies. These options include: reinforcement of education or change in VKA drugs in case of documented therapeutic fluctuations, adjunction of aspirin, change to direct oral anticoagulants, or percutaneous left-appendage closure.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis IV: Nursing Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease IV: Preventive Measures

